Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor

INTRODUCTION: Cobicistat (COBI) is a pharmacoenhancer and one of the components of ECF/TDF (elvitegravir/cobicistat/emtricitabine/tenofovir DF), which is approved in treatment-naïve HIV patients with creatinine clearance (CrCl) ≥70 mL/min. Study 118 assessed the renal safety of COBI-containing regim...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Martin, McDonald, Cheryl, Moyle, Graeme, Martorell, Claudia, Ramgopal, Moti, Laplante, Francois, Curley, Joanne, Graham, Hiba, Tran-Muchowski, Cecilia, Liu, Yapei, Rhee, Martin, Szwarcberg, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P292
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225380/
https://www.ncbi.nlm.nih.gov/pubmed/25397568
http://dx.doi.org/10.7448/IAS.17.4.19824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225380/
https://www.ncbi.nlm.nih.gov/pubmed/25397568
http://dx.doi.org/10.7448/IAS.17.4.19824

Ejemplares similares